Experimental myocardial infarction upregulates circulating fibroblast growth factor-23

32Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

© 2015 American Society for Bone and Mineral Research.Myocardial infarction (MI) is a major cause of death worldwide. Epidemiological studies have linked vitamin D deficiency to MI incidence. Because fibroblast growth factor-23 (FGF23) is a master regulator of vitamin D hormone production and has been shown to be associated with cardiac hypertrophy per se, we explored the hypothesis that FGF23 may be a previously unrecognized pathophysiological factor causally linked to progression of cardiac dysfunction post-MI. Here, we show that circulating intact Fgf23 was profoundly elevated, whereas serum vitamin D hormone levels were suppressed, after induction of experimental MI in rat and mouse models, independent of changes in serum soluble Klotho or serum parathyroid hormone. Both skeletal and cardiac expression of Fgf23 was increased after MI. Although the molecular link between the cardiac lesion and circulating Fgf23 concentrations remains to be identified, our study has uncovered a novel heart-bone-kidney axis that may have important clinical implications and may inaugurate the new field of cardio-osteology.

Author supplied keywords

Cite

CITATION STYLE

APA

Andrukhova, O., Slavic, S., Odörfer, K. I., & Erben, R. G. (2015). Experimental myocardial infarction upregulates circulating fibroblast growth factor-23. Journal of Bone and Mineral Research, 30(10), 1831–1839. https://doi.org/10.1002/jbmr.2527

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free